Oct 17 (Reuters) - ** Shares of medical device maker Delcath Systems Inc up 5.8% at $10.06
** Co expects Q3 revenue of $11.2 mln, above analysts' average estimate of $9.45 mln, according to data compiled by LSEG
** Co says it recorded $10 mln in U.S. revenue in Q3 from commercialization of Hepzato Kit, a drug-device combination product for cancer treatment
** DCTH says $10 mln quarterly U.S. revenue milestone triggers $25 mln financing tranche, which it will utilize to support ongoing commercial launch and invest in new trials to expand indications it plans to initiate in 2025
** Co to announce quarterly financial results on Nov. 8
** Up to last close, stock up ~140.98% YTD
(Reporting by Rishab Shaju in Bengaluru)
((Rishab.Shaju@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.